Plasma-type gelsolin in subarachnoid hemorrhage: Novel biomarker today, therapeutic target tomorrow?

Sherry Hsiang Yi Chou, Eng H. Lo, Ming Ming Ning*

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

4 Scopus citations


There is growing interest in the potential neuroprotective properties of gelsolin. In particular, plasma-type gelsolin (pGSN) can ameliorate deleterious inflammatory response by scavenging pro-inflammatory signals such as actin and lipopolysaccharide. In a recent issue of Critical Care, Pan and colleagues report an important association between pGSN and subarachnoid hemorrhage (SAH) disease severity, and found pGSN to be a novel and promising biomarker for SAH clinical outcome. Previous research shows pGSN may be actively degraded by neurovascular proteases such as matrix metalloproteinases in the cerebral spinal fluid of SAH patients. Taken together, these results suggest that pGSN is not only a novel marker of SAH clinical outcome, but may also play an active mechanistic role in SAH, and potentially serve as a future therapeutic target.

Original languageEnglish (US)
Article number101
JournalCritical Care
Issue number1
StatePublished - Jan 6 2014
Externally publishedYes

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine


Dive into the research topics of 'Plasma-type gelsolin in subarachnoid hemorrhage: Novel biomarker today, therapeutic target tomorrow?'. Together they form a unique fingerprint.

Cite this